Comments

TransMedics Group Analyst Ratings

TMDXNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$122.36

-0.79-0.64%

Last update: Dec 16, 2:14 PM

Overview News Earnings Options Guidance

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$178.00

Lowest Price Target¹

$70.00

Consensus Price Target¹

$124.69

TransMedics Group Analyst Ratings and Price Targets | NASDAQ:TMDX | Benzinga

TransMedics Group Inc has a consensus price target of $124.69 based on the ratings of 17 analysts. The high is $178 issued by Stephens & Co. on August 2, 2024. The low is $70 issued by JP Morgan on November 7, 2023. The 3 most-recent analyst ratings were released by Needham, Morgan Stanley, and Canaccord Genuity on December 8, 2025, December 2, 2025, and October 30, 2025, respectively. With an average price target of $149.33 between Needham, Morgan Stanley, and Canaccord Genuity, there's an implied 22.04% upside for TransMedics Group Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Aug

Sep

Oct

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Needham

Morgan Stanley

Canaccord Genuity

Piper Sandler

Jefferies

¹calculated from analyst ratings

Analyst Ratings for TransMedics Group

					Get Alert
Dec 8, 2025	35.67%	Mike MatsonNeedham 61%	148 166	Previous Buy Current Buy	Get Alert
Dec 2, 2025	10.33%	Patrick WoodMorgan Stanley 54%	123 135	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 30, 2025	20.14%	William PlovanicCanaccord Genuity 61%	142 147	Previous Buy Current Buy	Get Alert
Oct 30, 2025	14.42%	Matt O'BrienPiper Sandler 53%	140 145	Previous Overweight Current Overweight	Get Alert
Oct 23, 2025	20.95%	Mike MatsonNeedham 61%	148	Previous Hold Current Buy	Get Alert
Oct 14, 2025	16.05%	William PlovanicCanaccord Genuity 61%	142 142	Previous Buy Current Buy	Get Alert
Oct 13, 2025	18.5%	Young LiJefferies 30%	145	Previous Initiates Current Buy	Get Alert
Sep 16, 2025	26.68%	Daniel MarkowitzEvercore ISI Group 71%	155	Previous Initiates Current Outperform	Get Alert
Sep 4, 2025	-6.02%	Thomas StephanStifel 52%	115	Previous Initiates Current Hold	Get Alert
Aug 25, 2025	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Aug 1, 2025	0.52%	Patrick WoodMorgan Stanley 54%	115 123	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 15, 2025	16.05%	William PlovanicCanaccord Genuity 61%	129 142	Previous Buy Current Buy	Get Alert
Jun 17, 2025	22.59%	Suraj KaliaOppenheimer 62%	130 150	Previous Outperform Current Outperform	Get Alert
Jun 17, 2025	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Jun 4, 2025	18.5%	Matt O'BrienPiper Sandler 53%	125 145	Previous Overweight Current Overweight	Get Alert
Jun 3, 2025	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
May 9, 2025	6.24%	Suraj KaliaOppenheimer 62%	125 130	Previous Outperform Current Outperform	Get Alert
May 9, 2025	2.16%	Matt O'BrienPiper Sandler 53%	105 125	Previous Overweight Current Overweight	Get Alert
Apr 29, 2025	-14.19%	Matt O'BrienPiper Sandler 53%	90 105	Previous Overweight Current Overweight	Get Alert
Apr 23, 2025	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Mar 26, 2025	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Mar 11, 2025	-15%	William PlovanicCanaccord Genuity 61%	104 104	Previous Buy Current Buy	Get Alert
Feb 5, 2025	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Dec 17, 2024	-38.71%	Allen GongJP Morgan 52%	75 116	Previous Overweight Current Neutral	Get Alert
Dec 11, 2024	-26.45%	Matt O'BrienPiper Sandler 53%	90 110	Previous Overweight Current Overweight	Get Alert
Dec 11, 2024	-1.93%	Joe VruwinkBaird 69%	120 150	Previous Outperform Current Outperform	Get Alert
Dec 11, 2024	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Dec 3, 2024	2.16%	Suraj KaliaOppenheimer 62%	125 125	Previous Outperform Current Outperform	Get Alert
Dec 3, 2024	—	Mike MatsonNeedham 61%	—	Previous Hold Current Hold	Get Alert
Nov 22, 2024	-10.92%	Mike MatsonNeedham 61%	109 109	Previous Buy Current Hold	Get Alert
Nov 20, 2024	-10.1%	Matt O'BrienPiper Sandler 53%	110 180	Previous Overweight Current Overweight	Get Alert
Nov 20, 2024	-15%	William PlovanicCanaccord Genuity 61%	104 109	Previous Buy Current Buy	Get Alert
Nov 18, 2024	-1.93%	Joshua JenningsTD Cowen 56%	120 175	Previous Buy Current Buy	Get Alert
Oct 29, 2024	47.11%	Matt O'BrienPiper Sandler 53%	180 180	Previous Overweight Current Overweight	Get Alert
Oct 29, 2024	2.16%	Suraj KaliaOppenheimer 62%	125 200	Previous Outperform Current Outperform	Get Alert
Oct 29, 2024	-5.2%	Allen GongJP Morgan 52%	116 173	Previous Overweight Current Overweight	Get Alert
Oct 29, 2024	-10.92%	Jason MillsCanaccord Genuity 81%	109 169	Previous Buy Current Buy	Get Alert
Oct 29, 2024	22.59%	Joe VruwinkBaird 69%	150 200	Previous Outperform Current Outperform	Get Alert
Oct 29, 2024	-10.92%	Mike MatsonNeedham 61%	109 208	Previous Buy Current Buy	Get Alert
Oct 7, 2024	47.11%	Matt O'BrienPiper Sandler 53%	180 180	Previous Overweight Current Overweight	Get Alert
Sep 24, 2024	63.45%	Joe VruwinkBaird 69%	200	Previous Initiates Current Outperform	Get Alert
Aug 23, 2024	69.99%	Mike MatsonNeedham 61%	208 208	Previous Buy Current Buy	Get Alert
Aug 21, 2024	69.99%	Mike MatsonNeedham 61%	208	Previous Initiates Current Buy	Get Alert
Aug 2, 2024	45.47%	George SellersStephens & Co. 37%	151 178	Previous Overweight Current Overweight	Get Alert
Aug 1, 2024	47.11%	Matt O'BrienPiper Sandler 53%	170 180	Previous Overweight Current Overweight	Get Alert
Aug 1, 2024	38.12%	Jason MillsCanaccord Genuity 81%	117 169	Previous Buy Current Buy	Get Alert
Aug 1, 2024	63.45%	Suraj KaliaOppenheimer 62%	125 200	Previous Outperform Current Outperform	Get Alert
Jul 15, 2024	18.5%	Patrick WoodMorgan Stanley 54%	104 145	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 15, 2024	38.93%	Matt O'BrienPiper Sandler 53%	120 170	Previous Overweight Current Overweight	Get Alert
Jun 21, 2024	-1.93%	Matt O'BrienPiper Sandler 53%	120 120	Previous Overweight Current Overweight	Get Alert
Jun 7, 2024	43.02%	Joshua JenningsTD Cowen 56%	130 175	Previous Buy Current Buy	Get Alert
Jun 4, 2024	23.41%	George SellersStephens & Co. 37%	151	Previous Initiates Current Overweight	Get Alert
May 1, 2024	-4.38%	Jason MillsCanaccord Genuity 81%	102 117	Previous Buy Current Buy	Get Alert
May 1, 2024	6.24%	Joshua JenningsTD Cowen 56%	100 130	Previous Buy Current Buy	Get Alert
May 1, 2024	3.79%	Allen GongJP Morgan 52%	105 127	Previous Overweight Current Overweight	Get Alert
May 1, 2024	-1.93%	Matt O'BrienPiper Sandler 53%	95 120	Previous Overweight Current Overweight	Get Alert
May 1, 2024	2.16%	Suraj KaliaOppenheimer 62%	105 125	Previous Outperform Current Outperform	Get Alert
Mar 28, 2024	-22.36%	Matt O'BrienPiper Sandler 53%	95	Previous Initiates Current Overweight	Get Alert
Feb 28, 2024	-22.36%	Cecilia FurlongMorgan Stanley 50%	75 95	Previous Equal-Weight Current Equal-Weight	Get Alert
Feb 27, 2024	-14.19%	Allen GongJP Morgan 52%	87 105	Previous Overweight Current Overweight	Get Alert
Feb 27, 2024	-14.19%	Suraj KaliaOppenheimer 62%	92 105	Previous Outperform Current Outperform	Get Alert
Dec 4, 2023	-38.71%	Cecilia FurlongMorgan Stanley 50%	54 75	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 7, 2023	-42.79%	Thomas AllenJP Morgan 70%	67 70	Previous Overweight Current Overweight	Get Alert
Nov 7, 2023	-55.87%	Cecilia FurlongMorgan Stanley 50%	50 54	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 13, 2023	-59.14%	Cecilia FurlongMorgan Stanley 50%	50 81	Previous Equal-Weight Current Equal-Weight	Get Alert
Aug 4, 2023	-10.1%	Joshua JenningsTD Cowen 56%	95 110	Previous Outperform Current Outperform	Get Alert
Jul 19, 2023	—	—	—	Previous Initiates Current Outperform	Get Alert
May 18, 2023	-29.72%	William PlovanicCanaccord Genuity 61%	86 91	Previous Buy Current Buy	Get Alert
May 3, 2023	-33.8%	Cecilia FurlongMorgan Stanley 50%	74 81	Previous Current Equal-Weight	Get Alert
May 2, 2023	-26.45%	Suraj KaliaOppenheimer 62%	85 90	Previous Current Outperform	Get Alert
Feb 23, 2023	-38.71%	Joshua JenningsCowen & Co. 56%	70 75	Previous Current Outperform	Get Alert
Feb 23, 2023	-36.25%	William PlovanicCanaccord Genuity 61%	68 78	Previous Current Buy	Get Alert
Feb 23, 2023	-33.8%	Thomas AllenJP Morgan 70%	67 81	Previous Current Overweight	Get Alert
Feb 23, 2023	-30.53%	Suraj KaliaOppenheimer 62%	55 85	Previous Current Outperform	Get Alert
Feb 23, 2023	-39.52%	Cecilia FurlongMorgan Stanley 50%	63 74	Previous Current Equal-Weight	Get Alert
Jan 6, 2023	-48.51%	Cecilia FurlongMorgan Stanley 50%	54 63	Previous Current Equal-Weight	Get Alert

FAQ

What is the target price for TransMedics Group (TMDX) stock?

The latest price target for TransMedics Group (NASDAQ:TMDX) was reported by Needham on December 8, 2025. The analyst firm set a price target for $166.00 expecting TMDX to rise to within 12 months (a possible 35.67% upside). 24 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for TransMedics Group (TMDX)?

The latest analyst rating for TransMedics Group (NASDAQ:TMDX) was provided by Needham, and TransMedics Group maintained their buy rating.

When was the last upgrade for TransMedics Group (TMDX)?

The last upgrade for TransMedics Group Inc happened on October 23, 2025 when Needham raised their price target to $148. Needham previously had a hold for TransMedics Group Inc.

When was the last downgrade for TransMedics Group (TMDX)?

The last downgrade for TransMedics Group Inc happened on December 17, 2024 when JP Morgan changed their price target from $116 to $75 for TransMedics Group Inc.

When is the next analyst rating going to be posted or updated for TransMedics Group (TMDX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransMedics Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransMedics Group was filed on December 8, 2025 so you should expect the next rating to be made available sometime around December 8, 2026.

Is the Analyst Rating TransMedics Group (TMDX) correct?

While ratings are subjective and will change, the latest TransMedics Group (TMDX) rating was a maintained with a price target of $148.00 to $166.00. The current price TransMedics Group (TMDX) is trading at is $122.36, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.